Skip to content

Study on the Clinical effect and Mechanism of Wenjingyangxueafter severe intrauterine adhesion Separation

Study on the Clinical effect and Mechanism of Wenjingyangxueafter severe intrauterine adhesion Separation

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066198
Enrollment
Unknown
Registered
2022-11-28
Start date
2022-12-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrauterine adhesion

Interventions

Experimental group:Wenjingyangxue mixture combined with sequential therapy of estrogen and progesterone
Control group:sequential therapy of estrogen and progesterone

Sponsors

The First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. All patients were diagnosed as severe uterine adhesion by hysteroscopy according to the classification and scoring standard of American Reproductive Association; 2. This is the first time that uterine adhesion has been found, and there are fertility requirements; 3. Patients who did not receive hormone therapy before operation; 4. Regular menstruation or normal ovulation by recent B-ultrasound monitoring, or anti-Mullerian hormone (anti-Mullerrianhormone, AMH) test did not indicate a decrease in ovarian reserve function; 5. There are no surgical contraindications and contraindications for the use of estrogen and progesterone or Wenjingyangxue mixture; 6. Patients with amenorrhea need to rule out amenorrhea caused by dysfunction of other parts.

Exclusion criteria

Exclusion criteria: 1. Those who have fertility requirements but whose spouse's semen examination is abnormal; 2. Patients who are allergic to the drugs used in this study; 3. Have genital tuberculosis, polycystic ovary syndrome, endometriosis, submucous myoma of uterus, endometrial polyps, adenomyosis and other diseases affecting pregnancy; 4. Patients with serious heart, liver, kidney diseases or thrombotic diseases.

Design outcomes

Primary

MeasureTime frame
American Fertility Society score;Endometrial thickness;

Countries

China

Contacts

Public ContactZhi Zhifu

The First Affiliated Hospital of Guangxi Medical University,6 Shuangyong Road, Qingxiu District, Nanning, Guangxi

zhizhifu525@163.com+86 159 9435 1175

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026